Openbookopenbook
Equity
TLX
+0.0 · +0.00%
USD · NASDAQ

Telix Pharmaceuticals Limited(TLX) Stock Analysis | Healthcare

USD --+0.00%
Reward51Moderate
Risk56Medium-High
75%Data
Thin 4% profit margin · Revenue growing 22% YoY
Profitless Growth
Market Cap:3.84Bn
ⓘ
Reward Rating
51
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
56
Medium-High
Risk Assessment
7 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on TLX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for TLX, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $21.22.

What is Telix Pharmaceuticals Limited?

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.

TLX · Verdict

Moderate reward · elevated risk

TLX stands out on growth and volatility, but watch the valuation signal.

Based on 88% data coverage

TLX · Verdict

What’s working & what to watch

Strengths 2

  • Growth74/100

    Rev +96.0% CAGR · earnings -53.2%

  • Volatility65/100

    Above average

Watchouts 4

  • Valuation0/100

    P/E 161.3× · PEG 5.10

  • Balance sheet16/100

    Interest covered 0.9×

  • Cash flow26/100

    -7% free-cash-flow margin

  • Profitability44/100

    -1% net margin · 7% ROE

Model-based scoring. For information only — not financial advice.

What is Telix Pharmaceuticals Limited?

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 3.84B, and a P/E ratio of 113.3x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (51)

The scoring profile indicates limited reward potential at this time, with growth and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

IDYAMid Cap / 3.8B market cap
Ideaya Biosciences Inc
Compare
GNNSFMid Cap / 3.8B market cap
Genscript Biotech Corporation
Compare
CPRXMid Cap / 3.9B market cap
Catalyst Pharmaceuticals Inc
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap3.84B
P/E Ratio113.3
Dividend YieldN/A
Beta0.6
Insider Activity
12M windowNo data
No insider activity data available for this ticker.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.